CARDIOLOGY CLINICAL RESEARCH


Welcome to the University of South Alabama Division of Cardiology Clinical Research Trials website. Please click on the name of the trial to link to the ClinicalTrial.gov website for further information. Feel free to contact us at the phone number listed below for further information.



HEART-FID

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency.

Protocol Number:  1VIT15043

Principal Investigator:  Christopher Malozzi, DO

Currently enrolling

Objective: The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency.

Kellie and I will work on the Research Board in the conference room.  Please let me know if you want any other information.

CLEAR

A Randomized, Double-Blind, Placebo-Controlled study to assess the effects of  bempedoic acid (ETC-1002) on the Occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant.

Protocol Number:  1002-043

Principal Investigator:  Bassam Omar, MD, PhD

Currently enrolling

Objective:  to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

UPSTREAM

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Acute Coronary Syndrome (UPSTREAM): An ED-Based Clinical Registry.

Protocol Number:  NCT02271022

Principal Investigator:  G. Mustafa Awan, MD

Currently enrolling

Objective:  to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by characterizing and following the ED and peri-ED use of advanced OAP (Oral Anti-Platelet) agents.

 

GLORIA-AF

Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients with Atrial Fibrillation

Protocol Number:  1160.129

Principal Investigator:  Michael V. Cohen, MD

Enrollment Closed

Objective:  to investigate the patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in non-valvular atrial fibrillation (AF) patients.  To collect real world data on important outcome events of antithrombotic treatments for the prevention of stroke. 



For information please contact Cherie Revere at (251) 471 - 7027

 

Email Newsletters

Connect With Us